Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

被引：0
|
作者：
Shukui Qin
Jin Li
Haijun Zhong
Chuan Jin
Lili Chen
Xianglin Yuan
Qingxia Fan
Kehe Chen
Peiguo Cao
Jianjun Xiao
Da Jiang
Tao Zhang
Hongyu Zhang
Xicheng Wang
Wei Wang
Lin Han
Qingyu Wang
Jun Zhu
机构：
[1] Eastern Theater General Hospital of PLA China,Department of Oncology, Qinhuai Medical Area
[2] Tongji University Shanghai East Hospital,Department of Oncology
[3] Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Department of Abdominal Oncology
[4] Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Department of Oncology
[5] Taizhou First People’s Hospital,Department of Hematology and Oncology
[6] Tongji Hospital,Department of Oncology
[7] Huazhong University of Science and Technology,Department of Oncology
[8] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[9] The People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Oncology
[10] The Third Xiangya Hospital of Central South University,Chemotherapeutic Department
[11] Zhongshan City People’s Hospital,Department of Oncology
[12] The Fourth Hospital of Hebei Medical University,Department of Oncology
[13] The First Affiliated Hospital of Chongqing Medical University,Cancer Center
[14] The Fifth Affiliated Hospital Sun Yat-sen University,Department of Oncology
[15] The First Affiliated Hospital of Guangdong Pharmaceutical University,Department of Gastrointestinal Oncology
[16] The First People’s Hospital of Foshan,undefined
[17] Shanghai Henlius Biotech,undefined
[18] Inc.,undefined
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2249 / 2249
相关论文
共 50 条
  • [31] Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study.
    Li, Jian-Xu
    Su, Ting-Shi
    Lin, Xiao-Feng
    Chen, Yi-Tian
    Liang, Shi-Xiong
    Xiang, Bang-De
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
    Chen, Xiaozhong
    Wang, Wei
    Zou, Qingfeng
    Zhu, Xiaodong
    Lin, Qin
    Jiang, Yi
    Sun, Yan
    Shen, Liangfang
    Wang, Lin
    Zou, Guorong
    Lin, Xiaoyan
    Lin, Shaojun
    Li, Minying
    Wang, Ying
    Xu, Ruilian
    Ao, Rui
    Wang, Rensheng
    Lin, Haifeng
    Huang, Shuang
    Xu, Tingting
    Li, Wenting
    Xia, Mengying
    Xia, Yu
    Wang, Zhongmin
    Li, Baiyong
    Li, Jingao
    Hu, Chaosu
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [33] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [34] Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
    Zhang, Panpan
    Shi, Si
    Xu, Jianming
    Chen, Zhendong
    Song, Lijie
    Zhang, Xing
    Cheng, Ying
    Zhang, Yanqiao
    Ye, Feng
    Li, Zhiping
    Yin, Fei
    Ji, Dongmei
    Gao, Heli
    Li, Yi
    Chen, Wei
    Yang, Minjie
    Weng, Desheng
    Wu, Chunjiao
    Ma, Yue
    Sheng, Wang
    Zhao, Yaqin
    Yin, Xiaolei
    Shen, Weina
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Tan, Panfeng
    Xu, Qian
    Lu, Min
    Shen, Lin
    EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [35] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    BMC MEDICINE, 2022, 20 (01)
  • [36] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Zhengbo Song
    Guangyuan Lou
    Yina Wang
    Zhiping Yang
    Wenxian Wang
    Yongling Ji
    Shiqing Chen
    Chunwei Xu
    Xiao Hu
    Yiping Zhang
    BMC Medicine, 20
  • [37] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial.
    Qiu, Miaozhen
    Wang, De-Shen
    Sun, Yu-Ting
    Zhao, Qi
    Guan, Wen-Long
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
    John M. Slopis
    Octavio Arevalo
    Cynthia S. Bell
    Adelaide A. Hebert
    Hope Northrup
    Roy F. Riascos
    Joshua A. Samuels
    Keri C. Smith
    Patti Tate
    Mary Kay Koenig
    Drugs in R&D, 2018, 18 : 295 - 302
  • [40] Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
    Slopis, John M.
    Arevalo, Octavio
    Bell, Cynthia S.
    Hebert, Adelaide A.
    Northrup, Hope
    Riascos, Roy F.
    Samuels, Joshua A.
    Smith, Keri C.
    Tate, Patti
    Koenig, Mary Kay
    DRUGS IN R&D, 2018, 18 (04) : 295 - 302
12345